Roger, The simple fact is this company has more clinical history and track record than STEP. You need to consider all clinical reuslts to date, not just this unexcusable mishap with STEP.
I certainly think we need a conference call from management with more detail. That said, I don't think, from what I've read on this board, that Mac disclosed any inforamtion that was not inculded or deductible from the releases.
I would like to see one of two things ASAP: Mac step in and buy more shares, or Mac step down and resign. I am not expecting a resignation, and he likely has inside info that could preclude him from an purchases or sales. But, if the company really doesn't know STEP results, maybe he could buy. STEP UP MAC (PUN INTENDED).
Or... maybe the company really does have other opportunies beyond Ampio. They report it as it develops and becomes material info. They risk all their potential gains if they don't. Stay skeptical, but a bit more patience is warranted. Maybe a day, maybe a week or two...
Main news that will move AMPE is results of the STEP pivotal trial. These are due out sometime in August. They could be any day now. Today's release was not related to the STEP trial.
You're delusional if your comparing Amazon to Atlatsa... They do both start with the letter "A"
Really? Not sure what earnings you see, but I see a loss to ATL shareholders of $6.973 million Canadian for the quarter. Not sure how penny per share loss translates to a gain in your wold.
I sold donper some covered calls today for Aug 7.5. Buyers clearly think STEP will be out this week. My guess is next week...
Believe me, I hope I'm wrong, and it goes much higher. But, the reality is 9.07 is a 30% gain from secondary price of $7. I think we'll run into resistance somewhere between $9-$10, but we'll eventually break through to the double digits... This is a single day guess, and nothing more than a guess. I like everyone else's higher guesses better, but they are all guesses...
July 31 short interest data is out. AMPE shares short at 7/31 was 6.403 million shares, up from 6.286 million shares on 7/15. The increase of 116 thousand shares makes sense given late july price action. Days to cover stand at 11 at 7/31. AMPE was the 14th largest short position of all the NYSE MKT stocks as a percentage of float (13.2% of floating shares are sold short at 7/31).
Give me positive STEP! I'm ready for the pop, and to see some covering!
See 2011 10k (issued in 2012). Reference Related Party Transactions on page 59 and 60. He invested cash in several transactions listed.
Remember, we're in the dog days of summer. Most instututional investors are at the beach. This will slowly grind down in price until STEP news is released. This will move on institutional buying on news, and right now, most institutional buyers are ordering a cocktail at the beach club. I'm going to do the same, and continue to wait for STEP. This could easily move up or down $1 between now and STEP release.